author-photo

D. Daniel

Sarah Cannon Research Institute

43

Papers

4145

Citations

Citation Trend

Filter By

Papers (32) Sort By

Journal Conference Others

Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer

2019 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (184)
LBA2Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
P1.16-06 Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%

2018 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
LBA64nab-paclitaxel + carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND.sqm study

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
233O Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes

2018 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT

2018 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (18)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

2018 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (1207)
Identifying and interpreting actionable molecular alterations from next-generation sequencing results in the community: A Sarah Cannon molecular cancer conference.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
P1.16-04 Outcomes of Patients <70 or ≥70 Years of Age in PACIFIC

2018 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo‐controlled phase 2 trial with correlated serum proteomic signatures

2018 Cancer
Show All
- Source
- Cite
- Save
Citations (8)